ESPERITE (ESP) : L1 Capital invests for total EUR 500K today by subscribing to the Tenth tranche (EUR 250K)
ESPERITE (ESP) : L1 Capital invests for total EUR 500K today by subscribing to the Tenth tranche (EUR 250K) and shows confidence by investing additionally EUR 250K under the same conditions.
Amsterdam, The Netherlands – 9 November 2017
Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announces that today the Tenth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the “Notes”) with a principal amount of EUR 10,000 each under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the “Agreement”).
In addition to the Tenth tranche, another EUR 250,000 of Notes is issued to L1 Capital under the same conditions as the Tenth tranche. The overall EUR 500,000 of Notes are issued with 385,273 share subscription warrants attached (the “Warrants”).
The Notes and the Warrants shall have the same characteristics as those described in the Group’s press release dated 8 March 2017.
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – firstname.lastname@example.org or visit the websites at www.esperite.com www.genoma.com and www.cryo-save.com.
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Esperite in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), it being specified that the securities of Esperite have not been and will not be registered within the US Securities Act. Esperite does not intend to register securities or conduct a public offering in the United States of America.